Foresight Capital's model of investing across early, middle, and late stages from one fund provides a unique advantage. Their understanding of late-stage market needs and challenges directly informs and improves their selection process for early-stage companies, creating a powerful feedback loop that specialized VCs lack.

China has created a National Venture Capital Guidance Fund, a novel instrument designed to act as a public-private angel investor. This model leverages state financing alongside private VC expertise to more efficiently allocate capital into strategic, early-stage technology companies, bypassing traditional inefficient state funding.

A massive influx of capital into Chinese biotech, followed by a public market slowdown, left many innovative companies "trapped" without funding. This created a unique opportunity for Western pharma and VCs to license high-quality assets, driving pharma's China deal volume from single digits to nearly 50%.

Jeremy Levin outlines China's deliberate, 25-year strategic plan for biotech, moving from API production to CROs, attracting scientific talent, creating lookalikes, and now developing novel medicines. He warns that unless the U.S. treats biotech as a strategic asset, China's state-driven approach will make it the dominant innovator within five years, partly funded by Western pharma investments.

In stark contrast to the US, Chinese investors are accelerating funding for early-stage cell and gene therapies, which now account for 29% of seed/Series A rounds. These firms are specifically backing technologies like NK cell therapies, which have fallen out of favor in the West, creating a divergent global innovation strategy.

To bridge its translational research gap, Japan’s Agency of Medical Research and Development offers a unique fund. For qualified startups, it matches every dollar of venture capital investment with two dollars of non-dilutive government funding, providing crucial capital to advance early-stage assets without giving up equity.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.

Renowned gene therapy pioneer Jim Wilson was forced to spin out ultra-rare disease programs into a new company after his initial venture failed to attract VC funding. This demonstrates that even elite scientific leadership cannot overcome investor disinterest in this segment without powerful, predictable government incentives like transferable priority review vouchers.

A biotech boom in China, fueled by returning scientists and VC funding, hit a wall when public market access was restricted. This liquidity crunch left many high-quality companies with promising assets undervalued and in need of capital, creating a prime investment window for savvy foreign investors to acquire technology.